Sunitinib in the treatment of tubulocystic carcinoma of the kidney. A case report

Annals of Oncology

Volumn 19, Issue 9, 2008, Pages 1655-1656

  Mego, M ^a   Sycova Mila, Z ^b   Rejlekova, K ^e   Rychly, B ^c   Obertova, J ^a   Rajec, J ^a   Hes, O ^d   Mardiak, J ^b  

^a Faculty of Medicine of Comenius University and University Hospital Bratislava   (Slovakia)

^b CANCER RESEARCH INSTITUTE   (Slovakia)

^c SLOVAK MEDICAL UNIVERSITY   (Slovakia)

^d CHARLES UNIVERSITY   (Czech Republic)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOCETAXEL; GEMCITABINE; SUNITINIB;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER REGRESSION; CASE REPORT; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; DISEASE EXACERBATION; DYSPNEA; FATIGUE; HUMAN; KIDNEY CARCINOMA; KIDNEY TUBULOCYSTIC CARCINOMA; KIDNEY TUMOR; LYMPHADENOPATHY; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEPHRECTOMY; PLEURA EFFUSION; PLEURODESIS; PRIORITY JOURNAL; RETROPERITONEAL TUMOR; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; BIOPSY, NEEDLE; CARCINOMA, RENAL CELL; CARCINOMA, TRANSITIONAL CELL; CHEMOTHERAPY, ADJUVANT; DIAGNOSIS, DIFFERENTIAL; DRUG ADMINISTRATION SCHEDULE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; INDOLES; KIDNEY NEOPLASMS; KIDNEY TUBULES, COLLECTING; MALE; NEOPLASM STAGING; NEPHRECTOMY; PYRROLES; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 50849088606     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn408     Document Type: Article

References (7)

1. Milowsky MI, Rosmarin A, Tickoo SK et al. Active chemotherapy for collecting duct carcinoma of the kidney: A case report and review of the literature. Cancer 2002; 94: 111-116.
2. Yang XJ, Zhou M, Hes O et al. Tubulocystic carcinoma of the kidney: clinicopathologic and molecular characterization. Am J Surg Pathol 2008; 32: 177-187.
3. Oudard S, Banu E, Vieillefond A et al. Prospective multicenter phase II study of gemcitabine plus platinum salt for metastatic collecting duct carcinoma: Results of a GETUG (Groupe d'Etudes des Tumeurs Uro-Genitales) study. J Urol 2007; 177: 1698-1702.
4. de Wit R, Kruit WH, Stoter G et al. Docetaxel (Taxotere): An active agent in metastatic urothelial cancer: Results of a phase II study in non-chemotherapy-pretreated patients. Br J Cancer 1998; 78: 1342-2345.
5. Motzer RJ, Bukowski RM. Targeted therapy for metastatic renal cell carcinoma. J Clin Oncol 2006; 24: 5601-5608.
6. Choueiri TK, Plantade A, Elson P et al. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol 2008; 26: 127-131.
7. Gallagher DJ, Milowsky MI, Gerst SR et al. Phase II study of sunitinib in patients (pts) with relapsed or refractory urothelial carcinoma (UC). J Clin Oncol 2007; 25: 5080S.